Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression.

ABSTRACT:

Purpose

The mechanistic target of rapamycin complex 1 (mTORC1) signaling has been reported to regulate lens-induced myopia (LIM) in guinea pigs. To address the challenge of delivering lipophilic mTORC1 inhibitors to the posterior eye segment, we developed a novel topical ophthalmic formulation of everolimus, a second-generation rapamycin derivative available only orally, and evaluated its antimyopic efficacy, ocular pharmacokinetics, and safety.

Methods

Vehicle formulations were optimized for delivering everolimus to the RPE-choroid complex. The efficacy of different concentrations of everolimus eye drops was tested in 3-week-old male pigmented guinea pigs that underwent LIM. We examined mTORC1 signaling activation, axial elongation, refractive changes, and fundus morphology

SUBMITTER: Zhang R 

PROVIDER: S-EPMC12476157 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature